Aakaar Medical Technologies Limited
IPO Details
Subscription
Lot Distribution
Reservation
Company Fin.
₹0(0.00%)
Premium (ELP)
Aakaar Medical Technologies Limited's has transitioned to a publicly listed entity following its IPO debut on Jun 27, 2025 at the NSE exchange. The public offering successfully raised 37,50,400 Shares, consisting of 37,50,400 Sharesin new capital.
The IPO featured a competitive price range of ₹68 to ₹72 and minimum application size of 1600 shares. Market reception was evidenced through subscription activity between Jun 20, 2025 and Jun 24, 2025, reflecting investor appetite for the offering.
Allotment of shares was completed on Jun 25, 2025, distributing equity to successful applicants. The listing marked the beginning of the company's journey as a publicly traded corporation, subject to market dynamics and regulatory oversight.
Investors can bid starting from the minimum lot size specified for this IPO, and only in multiples of that lot size. The table below shows the minimum and maximum investment for retail investors and HNIs in terms of lots, quantity, and amount.
Aakaar Medical Technologies Limited, established in June 2013, is a company focused on aesthetic medical solutions, offering a wide range of specialized cosmetic products and devices. It primarily caters to dermatologists, plastic surgeons, aesthetic physicians, and cosmetologists. The company provides both its own brands—comprising products made in India and devices produced internationally—as well as imported brands from countries like South Korea, Spain, Italy, and Austria. These products are mainly supplied to professionals who either use them during treatments or sell them to end users. Aakaar’s offerings include skincare for home and professional use, injectable and contouring products, hair care solutions such as growth serums and tablets, medifacial kits, and various medical devices. These devices are used for treatments like urinary incontinence, tattoo removal, skin rejuvenation, laser hair reduction, and hair transplants. With a presence across India, the company has a strong network of 90 trained sales and service engineers, supporting a large and satisfied customer base. It distributes its products in multiple states including Delhi, Haryana, Punjab, Chandigarh, Uttarakhand, Uttar Pradesh, Bihar, West Bengal, Assam, Gujarat, Madhya Pradesh, Maharashtra, Karnataka, Telangana, and Tamil Nadu.
Note : "Calculations for ‘Shares Offered’ and ‘Total Amount’ are based on the highest price in the issue price band."
- Strong and Experienced Leadership: Managed by industry experts with deep domain knowledge in aesthetic medicine, driving strategic growth and operational excellence.
- Diversified Product Portfolio: Offers a comprehensive range of aesthetic devices and consumables, including both in-house and imported brands, catering to varied customer needs.
- Extensive Geographic Footprint: Maintains a robust pan-India presence through direct branches and an established consignment partner network, ensuring broad market coverage and accessibility.
- High Dependence on Imported Products: Significant reliance on third-party international brands makes the company vulnerable to supply chain interruptions, import delays, and foreign market uncertainties.
- Reliance on Contract Manufacturers: Heavy dependence on external manufacturing partners and loan license arrangements increases exposure to risks around production consistency, quality assurance, and regulatory compliance.
- Exposure to Cost Fluctuations: Volatile prices of raw materials, utilities, and logistics may adversely affect margins, operational efficiency, and overall financial performance.
- Dilip Ramesh Meswani
- Bindi Dilip Meswani
Aakaar Medical Technologies Limited
Bigshare Services Private Limited